Following BREXIT Decision, EMA to Relocate to Amsterdam, the Netherlands

08 Dec Following BREXIT Decision, EMA to Relocate to Amsterdam, the Netherlands

The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. This decision was taken in November by the EU 27 Member States in the margins of the General Affairs Council (Art. 50). The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest.

“We welcome today’s decision on the new location of EMA. Now that we finally know where our journey is taking us, we can take concrete actions for a successful move,” said EMA Executive Director Guido Rasi.

“Amsterdam ticks many of our boxes,” he continued. “It offers excellent connectivity and a building that can be shaped according to our needs. I am very grateful that the Member States took into account our requirements for business continuity and gave priority to the protection of public and animal health.

EMA has been based in London, UK, since it was established in 1995. It currently employs nearly 900 staff members at its headquarters in Canary Wharf, London.

"Our internal surveys have shown that a large majority of EMA staff would be willing to move with the Agency to Amsterdam. However even in this case, our activities will be impacted and we need to plan for this now to avoid the creation of gaps in knowledge and expertise.”

EMA has to relocate due to the United Kingdom’s decision to withdraw from the EU. Amsterdam was one of 19 offers to host EMA submitted by the Member States at the end of July 2017. Today’s decision on EMA’s new location follows an assessment of the bids by the European Commission and EMA.

“My staff and I are very honoured that so many Member States showed an interest in hosting EMA,” Professor Rasi commented. “The huge effort invested by the bidding countries to put together their proposals is a reflection of the Agency’s important role in the protection of public and animal health and the stimulation of a vibrant and innovative pharmaceutical industry.”

The decision today marks the official start of a challenging joint relocation project that will have to be delivered within extremely tight timelines whereby the relocation has to be completed by 30 March 2019.